AzurRx BioPharma - Home
 Clinical Trial Indication #Patients Highlights
Phase 2 Dose Escalation Trial

Option2 NCT04375878 
Cystic Fibrosis 30
  • Open label, crossover study comparing MS1819 to commercial PERTs
  • Study 2.2 mg/day and 4.4. mg/day using enteric capsules for gastric protection
Phase 2 Combination Therapy Dose Escalation Trial

Combination MS1819 PERT NCT04302662
Cystic Fibrosis
Severe EPI
  • Add MS1819 to commercial PERT to improve patient control
  • Primary endpoint to increase CFA from baseline value of <80% on PERT alone